Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934022 · ClinicalTrials.gov registry record · NA
Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients
A NA study, sponsored by Southern California Institute for Research and Education.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02934022: Completed NA study, sponsored by Southern California Institute for Research and Education.
NCT02934022 is a NA study that has completed, run by Southern California Institute for Research and Education. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02934022, a NA study, has completed, sponsored by Southern California Institute for Research and Education.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment regimen of these patients may result in an increase in their CD4 counts. As the patient would be continuing their prior regimen, they will likely continue with full control of viral replication.
Interventions
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-12 |
| Phase | NA |
What the finished NCT02934022 record still lists
NCT02934022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Maraviroc is the first listed.
NCT02934022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02934022 about?
NCT02934022 is a clinical study titled "Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients". Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment regimen of these patie...
What is the current status of trial NCT02934022?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2012-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02934022?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT02934022?
This trial is sponsored by Southern California Institute for Research and Education, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02934022's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia